A bridging study of Lu 25-109 in patients with probable Alzheimer's disease

Life Sciences

Volumn 62, Issue 3, 1997, Pages 195-202

  Sramek, John J ^a   Forrest, Misser ^b   Mengel, Helle ^b   Jhee, Stanford S ^a   Hourani, Jameel ^a   Cutler, Neal R ^a  

^a CALIFORNIA CLINICAL TRIALS   (United States)

^b H LUNDBECK A S   (Denmark)

Author keywords

Alzheimer's disease; Bridging study; Lu 25 109; Muscarinic agonist; Phase I trials

Indexed keywords

ALVAMELINE; MUSCARINIC M1 RECEPTOR AGONIST; MUSCARINIC M2 RECEPTOR ANTAGONIST; MUSCARINIC M3 RECEPTOR ANTAGONIST; PARTIAL AGONIST; PLACEBO; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CHOLINERGIC ACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERSALIVATION; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; VERTIGO;

EID: 0031566005     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(97)01087-4     Document Type: Article

References (18)

1. T. SUNDERLAND, P.N. TARIOT, and P.A. NEWHOUSE, Brain Res. Rev. 13 371-389 (1988).
2. K.C. RAFFAELE, A. BERARDI, P.P. MORRIS, S. ASTHANA, J.V. HAXBY, M.B. SCHAPIRO, S.I. RAPOPORT, and T.T. SONCRANT, Prog. Neuropsychopharmacol. Biol. Psychiatry 15 643-648 (1991).
3. S. GAUTHIER, R. LEBLANC, Y. ROBITAILLE, R. QUIRION, G. CARLSSON, M. BEAULIEU, R. BOUCHARD, D. DASTOOR, F. ERVIN, L. GAUTHIER et al., Can. J. Neurol. Sci. 13 394-402 (1986).
4. R.D. PENN, E.M. MARTIN, R.S. WILSON, J.H. FOX, and S.M. SAVOY, Neurology 38 219-222 (1988).
5. N.C. BODICK, W.W. OFFEN, A.I. LEVEY, N.R. CUTLER, S.G. GAUTHIER, A. SATLIN, H.E. SHANNON, G.D. TOLLEFSON, K. RASMUSSEN, F.P. BYMASTER, D.J. HURLEY, W.Z. POTTER, and S.M. PAUL, Arch. Neurol. 54 465-473 (1997).
6. P.J. WHITEHOUSE and K.S. AU, Prog. Neuro-Psychopharmacol. Biol Psychiatry 10 665-676 (1986).
7. N.R. CUTLER and J.J. SRAMEK, Alzheimer Dis. Assoc. Disord. 9 139-145 (1995).
8. N.R. CUTLER and J.J. SRAMEK, Eur. J. Clin. Pharmacol. 48 421-428 (1995).
9. N.R. CUTLER and J.J. SRAMEK, Pharmacological Treatment of Alzheimer's Disease: Molecular and Neurobiological Foundations, J.D. Brioni and M.W. Decker (eds.), 367-387, Wiley-Liss, New York (1997).
10. J.J. SRAMEK, A.J. SEDMAN, P.A. REECE, J. HOURANI, H. BOCKBRADER, and N.R. CUTLER, Life Sci. 57 503-510 (1995).
11. J.J. SRAMEK, D.J. HURLEY, T.S. WARDLE, J.H. SATTERWHITE, J. HOURANI, F. DIES, and N.R. CUTLER, J. Clin. Pharmacol. 35 800-806 (1995).
12. A. WALLAND, S. BURKARD, R. HAMMER, and W. TROGER. Life Sci. 60(13-14) 977-984 (1997).
13. P.A. REECE, H. BOCKBRADER, and A.J. SEDMAN, Clin. Exp. Pharmacol. Physiol. [Supp] 2158 (1992).
14. M.R. GOLDBERG, A. BARCHOWSKY, J. MCCREA, C. BEN-MAIMON, N. CAPRA, V. FITZPATRICK, and T.D. BJORNSSON, Presented at the Second International Springfield Symposium on Advances in Alzheimer Therapy (1991).
15. J.J. SRAMEK, G.A. BLOCK, S.A. REINES, S.F. SAWIN, A. BARCHOWSKY, and N.R. CUTLER, Life Sci. 56(5) 319-326 (1994).
16. S.K. PURI, R.S. HSU, I. HO, and H.B. LASSMAN, Curr. Ther. Res. 44 766-780 (1988).
17. S.K. PURI, I. HO, and H.B. LASSMAN, J. Clin. Pharmacol. 30 948-955 (1990).
18. N.R. CUTLER, M.F. MURPHY, R.J. NASH, P.L. PRIOR, and D.M. DELUNA, J. Clin. Pharmacol. 30 556-561 (1990).